How Not To Develop A Drug
This article was originally published in RPM Report
Executive Summary
What is the best way to encourage drug development in an unmet medical need? Chronic Fatigue Syndrome advocates argue that FDA should approve a drug—specifically Ampligen—even if it falls far short of reaching typical standards of evidence. FDA disagrees, and gained the backing of its advisory committee on that point. But the vote was close…
You may also be interested in...
Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting
FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.
FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
Invaluable Guidance: FDA’s Dean of Drug Reviews on “Enrichment Strategies”
FDA’s draft guidance on “Enrichment Strategies for Clinical Trials” fulfills an overdue goal from PDUFA IV. It also captures decades of wisdom from the agency’s senior drug review manager.